Ceapro : to Present at Noble Financial Capital Markets’ 12th Annual Investor Conference – Presentation with live webcast on Tuesday, January 19th at 2:30 p.m. ET

EDMONTON, ALBERTA - January 13, 2016 - Ceapro Inc. (TSX-V: CZO) ('Ceapro' or the 'Company'), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it will present at NobleCon12, the Noble Financial Capital Markets' 12th Annual Investor Conference, on Tuesday, January 19, 2016 at 2:30 p.m. ET in Sandpiper Bay, FL.

Gilles Gagnon M.Sc., MBA, Ceapro's President and Chief Executive Officer, will provide an overview of the Company's high-value, de-risked cosmeceuticals business and discuss the development plans for its pharmaceutical grade active ingredients avenanthramides and beta glucan. Ceapro is developing its two value drivers, avenanthramides and beta glucan, into different formulations with a long-term strategic vision to transition into other sectors including nutraceuticals and pharmaceuticals.

A live webcast of the presentation will be available on the Company's website at www.ceapro.com. The webcast replay will be available approximately two hours after the presentation ends and will be accessible for one month.

About Noble Financial Capital Markets
Noble Financial Capital Markets, established in 1984, is an equity-research driven, full-service, investment & merchant banking boutique focused on the healthcare, media & entertainment, technology and natural resources sectors. The company has offices in Boca Raton, New York, Boston and Los Angeles. In addition to the annual multi-sector NobleCon, each year Noble hosts numerous 'non-deal' corporate road shows and sector-specific conferences. For more information: www.noblefcm.com.

About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and 'active ingredients' from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company's website at www.ceapro.com.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

INVESTOR AND MEDIA CONTACT:
Jenene Thomas
Jenene Thomas Communications, LLC
T (US): 908-938-1475
E: [e-mail]

Source: Ceapro Inc.

Click here to download a PDF of this press release.

On January 13, 2016 / News